Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCT-001 (Canary Cure Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Canary Cure
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral
01
Overview
CCT-001 is an investigational small interfering RNA (siRNA) therapeutic being developed by Canary Cure for the treatment of metabolic disorders. The drug targets the endocannabinoid system and specific energy expenditure pathways to promote the browning or beigeing of white adipose tissue. By inducing this phenotypic switch in fat cells, CCT-001 aims to increase metabolic rate and energy consumption. Uniquely for an siRNA modality, CCT-001 is designed for oral administration with a monthly dosing schedule. It is currently in the preclinical stage of development, with ongoing efforts in lead optimization and IND-enabling studies.
02
Targets
CNR1 (Cannabinoid receptor 1)ZNF423 (Zinc finger protein 423)
Beyond the preview
Go deeper on CCT-001 (Canary Cure Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCT-001 (Canary Cure Therapeutics).